Table 1 Baseline patient characteristics with respect to cohesin mutation status.
Parameter | Cohesin mutated | Cohesin wildtype | p |
|---|---|---|---|
n/N (%) | 184/1615 (11.4) | 1426/1615 (88.3) | |
Age (years), median (IQR) | 57 (48.5-65.5) | 53 (44.0-65.0) | 0.112 |
Sex, n (%) | 0.643 | ||
female | 94 (49.7) | 683 (47.9) | |
male | 95 (50.3) | 743 (52.1) | |
Disease status, n (%) | |||
de novo | 141 (79.7) | 1198 (84.9) | 0.133 |
sAML | 30 (16.9) | 165 (11.7) | 0.050 |
tAML | 6 (3.4) | 48 (3.4) | 1.000 |
extramedullary disease, n (%) | 24 (12.7) | 190 (13.3) | 1.000 |
ELN-Risk 2022, n (%) | |||
favorable | 59 (31.2) | 518 (36.3) | 0.324 |
intermediate | 32 (1518/16156.9) | 392 (27.5) | 0.004 |
adverse* | 88 (46.6)* | 498 (34.9)* | 0.001* |
missing | 10 (5.3) | 18 (1.3) | |
Complex karyotype, n (%) | 0.022 | ||
No | 144 (92.9) | 1123 (86.4) | |
Yes | 11 (7.1) | 177 (13.6) | |
Normal karyotype, n (%) | <0.001 | ||
No | 46 (27.2) | 627 (47.0) | |
Yes | 123 (72.8) | 707 (53.0) | |
allogeneic HCT | |||
in first CR | 27 (14.7) | 217 (15.2) | 1.000 |
overall | 55 (30.0) | 464 (32.5) | 0.613 |
missing | 4 (2.2) | 0 | |
Laboratory, median (IQR) | |||
WBC (109/l) | 12.1 (3.2-41.1) | 20.4 (4.9-55.5) | 0.001 |
HB (mmol/l) | 6.0 (5.0-6.8) | 5.9 (5.1-7.0) | 0.764 |
PLT (109/l) | 49.0 (26.0-91.0) | 50.5 (27.0-95.0) | 0.899 |
LDH (U/l) | 455.5 (281.0-824.0) | 443.0 (771.0-281.0) | 0.558 |
PBB (%) | 25.5 (8.0-67.5) | 41.0 (13.0-74.0) | 0.020 |
BMB (%) | 54.0 (40.0-72.5) | 63.5 (45.0-79.5) | <0.001 |
